Integra LifeSciences Holdings Corporation
NASDAQ:IARTMedical - Devices
+$0.81 today
- Market cap
- $1.08B
- Beta
- 1.25
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$6.44
Volume 0.58M
Average 0.96M
IART Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Integra LifeSciences Holdings CorporationNASDAQ: IART
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was -$30.94M, compared with -$24.11M a year earlier.
Context
- Accumulated OCI amounted to 0.9% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Accumulated OCI increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -28.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (30.08M) USD
- Year-over-year change
- -9.1%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (30.08M) | -9.1% |
| FY2024 | 2024-12-31 | (27.57M) | -82.5% |
| FY2023 | 2023-12-31 | (15.11M) | -247.2% |
| FY2022 | 2022-12-31 | 10.27M | +122.7% |
| FY2021 | 2021-12-31 | (45.16M) | — |
Accumulated OCI vs competitors
How IART compares with its peers on the latest reported figures
- IART's Mar 2026 Accumulated OCI of -$30.94M is the 9th highest of the 11 companies compared; the peer median is -$500.
- Its year-over-year change of -28.3% is the lowest of 9, against a peer median of +31.1%.
- Accumulated OCI amounts to 0.9% of total assets for IART, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $20M | — | — | 0.2% | |
| Jun 2026 | $11.2M | +9.3% | — | 0.2% | |
| Mar 2026 | $142K | +105.6% | — | 0.0% | |
| Jun 2026 | $84K | -9.7% | -15.3% | 0.1% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$1K | +99.5% | — | 0.0% | |
| Mar 2026 | -$6.45M | +38.4% | — | 0.8% | |
| Mar 2026 | -$11.57M | +37.8% | — | 1.3% | |
| Mar 2026 | -$30.94M | -28.3% | — | 0.9% | |
| Mar 2026 | -$44.69M | +22.1% | — | 1.9% | |
| Jun 2026 | -$576M | +24.4% | — | 1.2% | |
| Peer median (excluding IART) | -$500 | +31.1% | -15.3% | 0.2% | |
Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 513.45M | 456.66M | 276.4M | 246.38M | 235.05M |
| Short-term Investments | 0 | 0 | 32.69M | 27.19M | 28.69M |
| Net Receivables | 243.24M | 263.47M | 259.33M | 272.37M | 278.85M |
| Inventory | 317.39M | 324.58M | 389.61M | 429.09M | 492.74M |
| Other Current Assets | 13.82M | 31.03M | 32.64M | 29.65M | 28.13M |
| Total Current Assets | 1.15B | 1.16B | 1.06B | 1.08B | 1.16B |
| Property, Plant & Equipment (Net) | 396.25M | 459.59M | 496.38M | 549.77M | 584.9M |
| Goodwill | 1.01B | 1.04B | 1.06B | 1.1B | 615.16M |
| Intangible Assets | 1.15B | 1.13B | 1.07B | 1.21B | 1.13B |
| Long-term Investments | 6.48M | 567.34M | 30.71M | 38.3M | 12.78M |
| Tax Assets | 56.95M | 45.99M | 46.08M | 34.92M | 69.85M |
| Other Non-current Assets | 9.96M | (510.15M) | 27.48M | 28.21M | 25.1M |
| Total Non-current Assets | 2.63B | 2.73B | 2.72B | 2.96B | 2.44B |
| Total Assets | 3.78B | 3.89B | 3.78B | 4.04B | 3.6B |
| Account Payables | 61.84M | 102.1M | 92.33M | 82.5M | 95.73M |
| Short-term Debt | 59.78M | 52.75M | 14.53M | 607.08M | 126.55M |
| Tax Payables | 0 | 0 | 0 | 0 | 3.65M |
| Deferred Revenue | 5.3M | 7.25M | 8.54M | 10.48M | 11.46M |
| Other Current Liabilities | 105.68M | 65.41M | 100.84M | 37.79M | 74.08M |
| Total Current Liabilities | 340.02M | 320.91M | 306.98M | 922.13M | 455.98M |
| Long-term Debt | 1.5B | 1.41B | 1.49B | 1.2B | 1.73B |
| Deferred Tax Liabilities | 45.79M | 63.34M | 35.32M | 60.83M | 5.66M |
| Deferred Revenue (Non-current) | 6.7M | 8.8M | 7.7M | 9.2M | 0 |
| Other Non-current Liabilities | 120.26M | 138.5M | 192.24M | 137.04M | 204.28M |
| Total Non-current Liabilities | 1.76B | 1.76B | 1.89B | 1.57B | 2.1B |
| Total Liabilities | 2.1B | 2.09B | 2.19B | 2.49B | 2.56B |
| Common Stock | 896K | 905K | 909K | 916K | 923K |
| Retained Earnings | 698.57M | 879.12M | 946.86M | 939.92M | 423.44M |
| Accumulated OCI | (45.16M) | 10.27M | (15.11M) | (27.57M) | (30.08M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.68B | 1.8B | 1.59B | 1.55B | 1.04B |
| Total Debt | 1.67B | 1.63B | 1.68B | 1.98B | 2.03B |
| Net Debt | 1.15B | 1.17B | 1.41B | 1.74B | 1.8B |
Integra LifeSciences Holdings Corporation
NASDAQ:IART
Intrinsic Alpha fair value
Locked
Current Price
$13.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.